The Virtuoso epigenomics platform, by ClearNote Health, measures active disease biology, from drug discovery through development, including dynamic insights into therapy response and resistance — all through a simple blood draw.
Assess levels of drug target activity for patient selection or target engagement assessment
Virtuoso analysis of cfDNA from blood provides consistent, reliable data across multiple timepoints, enhancing the ability to analyze therapeutic signatures of response throughout a study.
Virtuoso uncovers the biological underpinnings of drug response by analyzing epigenomic and genomic data, applicable from phase I-IV.
Virtuoso generates DNA epigenomic profiles to stratify subjects based on unique biological markers and ctDNA quantification.
Traditional drug development processes are challenged by limited tissue availability and lack of tools that can capture tumor evolution and biology that is driven by non-genetic mechanisms. The Virtuoso Epigenomics Platform is a groundbreaking whole genome sequencing and 5hmC enrichment solution designed to revolutionize translational research by revealing active disease biology to empower drug discovery and development.
Traditional drug development processes are challenged by limited tissue availability and lack of tools that can capture tumor evolution and biology that is driven by non-genetic mechanisms. The Virtuoso Epigenomics Platform is a groundbreaking whole genome sequencing and 5hmC enrichment solution designed to revolutionize translational research by revealing active disease biology to empower drug discovery and development.
ClearNote Health is a cancer detection company focused on enabling longer and healthier lives for high-mortality cancer patients.
Utilizing a standard blood draw, our proprietary epigenomic platform combines biology and artificial intelligence to provide a more comprehensive view of biology to identify DNA-based changes in biology as cancer develops.
Contact us with any questions about Virtuoso or ClearNote Health.